What is Eplontersen: Uses, Dosage, Side Effects and More

Eplontersen is a prescription medication that helps treat hereditary transthyretin amyloidosis (hATTR amyloidosis), a rare genetic condition where abnormal protein builds up in your body's organs and tissues. This targeted therapy works by reducing the production of a specific protein that causes problems in people with this inherited condition.

If you or someone you know has been diagnosed with hATTR amyloidosis, you're likely feeling overwhelmed by all the medical information coming your way. This medication represents an important treatment option that can help slow the progression of this condition and improve quality of life for many patients.

What is Eplontersen?

Eplontersen is a type of medication called an antisense oligonucleotide that specifically targets the genetic instructions your body uses to make transthyretin protein. Think of it as a molecular editor that tells your liver to produce less of the problematic protein that causes hATTR amyloidosis.

This medication belongs to a newer class of precision medicines designed to work at the genetic level. Unlike traditional medications that treat symptoms after they appear, eplontersen works upstream to reduce the root cause of the problem before it can damage your organs.

The drug comes as a pre-filled syringe that you inject under your skin once a month. This self-administered approach allows you to receive treatment in the comfort of your own home after proper training from your healthcare team.

What is Eplontersen Used For?

Eplontersen is specifically approved to treat hereditary transthyretin amyloidosis (hATTR amyloidosis), a rare genetic condition that affects multiple organs in your body. This disease occurs when your liver produces an abnormal version of the transthyretin protein, which then clumps together and deposits in your heart, nerves, and other tissues.

The medication is particularly helpful for people experiencing the polyneuropathy form of hATTR amyloidosis, which primarily affects your peripheral nerves. These are the nerves that carry signals between your brain and spinal cord to the rest of your body, controlling sensation and movement in your arms and legs.

Your doctor may recommend eplontersen if you have confirmed hATTR amyloidosis with polyneuropathy and are experiencing symptoms like numbness, tingling, pain, or weakness in your hands and feet. The medication can help slow the progression of these nerve-related symptoms and potentially prevent further nerve damage.

How Does Eplontersen Work?

Eplontersen works by using a sophisticated molecular approach to reduce the amount of transthyretin protein your liver produces. The medication contains specially designed genetic instructions that bind to the messenger RNA responsible for making transthyretin protein, essentially blocking the protein production process.

This is considered a moderately strong and highly targeted therapy because it addresses the underlying cause of hATTR amyloidosis rather than just managing symptoms. By reducing transthyretin protein production by approximately 80-90%, the medication can significantly decrease the amount of abnormal protein available to form harmful deposits in your organs.

The effects of eplontersen build up over time as your body's existing protein deposits are gradually cleared while new harmful deposits are prevented from forming. Most patients begin to see measurable improvements in their condition within 6 to 12 months of starting treatment, though individual responses can vary.

How Should I Take Eplontersen?

Eplontersen is given as a subcutaneous injection, which means you inject it into the fatty tissue just under your skin once every month. Your healthcare team will teach you or a family member how to prepare and give these injections safely at home.

You can take this medication with or without food since it's injected rather than swallowed. However, it's helpful to establish a routine around injection time to ensure you don't miss doses. Many patients find it easier to schedule their monthly injection for the same day each month.

Before each injection, you'll need to remove the pre-filled syringe from the refrigerator and let it reach room temperature for about 30 minutes. The injection sites should be rotated between your thigh, upper arm, or abdomen to prevent irritation. Always clean the injection site with alcohol before administering the medication.

Your healthcare provider will monitor your vitamin A levels regularly since eplontersen can reduce vitamin A in your body. You may need to take vitamin A supplements as directed by your doctor to maintain healthy levels.

How Long Should I Take Eplontersen For?

Eplontersen is typically a long-term treatment that you'll continue taking as long as it's providing benefit and you're tolerating it well. Since hATTR amyloidosis is a progressive genetic condition, stopping the medication would likely allow the disease to resume its natural course.

Your doctor will regularly assess how well the medication is working for you through various tests and evaluations. These might include nerve conduction studies, heart function tests, and assessments of your daily activities and quality of life. Based on these results, your healthcare team will determine whether to continue treatment.

Some patients may need to temporarily stop eplontersen if they experience significant side effects or if other health conditions develop that make continued treatment inadvisable. Your doctor will work with you to weigh the benefits and risks of continuing treatment based on your individual situation.

What Are the Side Effects of Eplontersen?

Like all medications, eplontersen can cause side effects, though not everyone experiences them. Most side effects are manageable and tend to improve as your body adjusts to the treatment over the first few months.

The most common side effects you might experience include reactions at the injection site such as redness, swelling, or tenderness where you received the shot. These local reactions are usually mild and resolve on their own within a few days of each injection.

Here are the more frequently reported side effects that patients experience:

• Injection site reactions (redness, swelling, bruising, or pain)
• Fatigue or feeling more tired than usual
• Muscle or joint pain
• Headache
• Nausea or stomach discomfort
• Cold-like symptoms such as runny nose or sore throat
• Dizziness or lightheadedness

These common side effects are generally mild to moderate and don't require stopping the medication. Your healthcare team can provide strategies to help manage these symptoms if they become bothersome.

More serious but less common side effects can occasionally occur and require immediate medical attention. While these are rare, it's important to be aware of them so you can seek help promptly if needed.

Here are the more serious side effects that require immediate medical attention:

• Severe allergic reactions with difficulty breathing, swelling of face or throat, or widespread rash
• Significant vitamin A deficiency symptoms like severe night blindness or dry eyes
• Severe injection site reactions that don't improve or worsen over time
• Unusual bleeding or bruising that doesn't resolve
• Signs of liver problems such as yellowing of skin or eyes, dark urine, or severe abdominal pain

If you experience any of these serious side effects, contact your healthcare provider immediately or seek emergency medical care. These reactions, while uncommon, need prompt evaluation and treatment.

Who Should Not Take Eplontersen?

Eplontersen isn't suitable for everyone, and your doctor will carefully review your medical history before prescribing this medication. The primary reason someone cannot take eplontersen is if they have a known severe allergy to the medication or any of its ingredients.

Pregnant women should not take eplontersen unless the potential benefits clearly outweigh the risks to both mother and baby. The medication can cross the placenta and may affect fetal development, so it's crucial to discuss pregnancy plans with your healthcare provider before starting treatment.

People with severe liver disease may need special monitoring or may not be candidates for eplontersen, since the medication works by affecting liver function. Your doctor will evaluate your liver health through blood tests before starting treatment and monitor it regularly afterward.

Here are the main groups of people who should use extra caution or avoid eplontersen:

• Pregnant women or those planning to become pregnant
• People with severe liver disease or liver failure
• Individuals with a history of severe allergic reactions to similar medications
• Those with active, uncontrolled bleeding disorders
• People taking certain medications that may interact with eplontersen
• Individuals with severe kidney disease requiring dialysis

Your healthcare provider will consider all these factors along with your overall health status when determining if eplontersen is right for you. They may also recommend additional monitoring or precautions based on your specific medical situation.

Eplontersen Brand Name

Eplontersen is sold under the brand name Wainua in the United States and other countries where it's approved. This brand name is what you'll see on your prescription label and medication packaging.

Wainua is manufactured by Ionis Pharmaceuticals and is available only through specialty pharmacies that have experience handling and distributing this type of medication. Your healthcare team will help coordinate with the appropriate pharmacy to ensure you receive your medication properly.

Since this is a newer medication, generic versions are not yet available. You'll need to use the brand name version, and your insurance company may require prior authorization before covering the cost of treatment.

Eplontersen Alternatives

Several other treatment options are available for people with hATTR amyloidosis, though each works differently and may be more suitable for different patients. Your doctor will help determine which treatment approach is best for your specific situation.

Patisiran (Onpattro) is another RNA-targeting medication that works similarly to eplontersen but is given as an intravenous infusion every three weeks instead of a monthly injection. Some patients prefer the IV approach, while others find the at-home injection more convenient.

Inotersen (Tegsedi) is another subcutaneous injection medication that also targets transthyretin production but requires more frequent blood monitoring due to potential effects on platelets and kidney function. This medication is given weekly rather than monthly.

Here are the main alternative treatments for hATTR amyloidosis:

• Patisiran (Onpattro) - IV infusion every 3 weeks
• Inotersen (Tegsedi) - weekly subcutaneous injection
• Tafamidis (Vyndaqel/Vyndamax) - daily oral medication that stabilizes transthyretin
• Diflunisal - an anti-inflammatory medication that may help stabilize transthyretin
• Liver transplantation - for select patients with severe disease

Each of these treatments has different benefits, risks, and administration requirements. Your healthcare team will consider factors like your disease severity, other health conditions, lifestyle preferences, and insurance coverage when recommending the best treatment option for you.

Is Eplontersen Better Than Inotersen?

Both eplontersen and inotersen are effective treatments for hATTR amyloidosis, but they have different advantages and disadvantages that make one more suitable than the other for different patients. Neither medication is universally "better" - the choice depends on your individual needs and circumstances.

Eplontersen offers the convenience of monthly injections compared to inotersen's weekly injections, which many patients find more manageable long-term. Additionally, eplontersen requires less frequent blood monitoring, as it doesn't typically affect platelet counts or kidney function to the same degree as inotersen.

However, inotersen has been available longer and has more extensive real-world experience, which some patients and doctors prefer. Some patients also respond better to one medication than the other, and switching between them may be an option if the first choice doesn't provide adequate results.

Here's how these medications compare in key areas:

• Dosing frequency: Eplontersen monthly vs. inotersen weekly
• Blood monitoring: Eplontersen requires less frequent monitoring
• Side effect profile: Both have injection site reactions, but inotersen may have more systemic effects
• Real-world experience: Inotersen has longer track record of use
• Effectiveness: Both show similar reductions in transthyretin protein production

Your doctor will help you weigh these factors along with your personal preferences, lifestyle, and other health considerations to determine which medication is most appropriate for your situation.